Month: May 2026

In a recent feature for Biospace, journalist Tristan Manalac spoke with Racura chairman Pete Smith about the difficulties in targeting the notoriously undruggable myc gene. Along with RIPK1, STING and alpha-synuclein, myc has left a trail of failed clinical trials, cancelled partnerships and sunk investments in their wake, said Manalac.

Read the full article here.

Clinical trials have advanced dramatically in precision, yet a large portion of chronic disease activity still occurs outside the clinic and outside traditional measurement windows. Nighttime symptoms, sleep‑related biomarkers and overnight deterioration are central to many conditions, but remain challenging to capture with diaries, morning recall or short‑duration assessments.

In this International Clinical Trials article, Albus Health CEO Mikesh Udani examines how continuous, passive monitoring is beginning to change that. He describes the longstanding gap between when disease manifests and when trials typically measure it — and how contactless technologies are now making it possible to capture objective nighttime physiology at scale, without adding burden to patients or sites.

The piece explores the evidence behind these approaches, including validation against clinical reference standards, long‑term usability data, and applications across asthma, COPD, heart failure, neurological conditions and safety monitoring. It also outlines the implications for trial design, from more sensitive endpoints to earlier detection of deterioration.

As continuous monitoring moves from exploratory pilots into protocol planning, it is reshaping how the industry understands treatment response, risk and disease biology, particularly in the domains that matter most to patients.

Read the full article here.

The CEO of One-carbon Tx, Dr Ana Slipicevic, spoke with Yilmaz Biter at BioPitch about her path from oncology research to leading a first‑in‑class clinical program at One‑carbon Therapeutics.

The conversation offers a clear look at the decisions, data, and translational focus shaping the work of this pioneering biotech.

Read the full interview here. 

Following Dr Giedrius Gasiunas’ presentation on the compact Cas12l CRISPR-Cas editor at the ASGCT Annual Meeting in Boston, a new GEN article highlights Caszyme’s development work on this promising genome editing platform.

Thanks to its compact size and C-rich PAM recognition, Cas12l opens exciting opportunities: expanding the CRISPR toolbox and positioning itself as a compelling alternative to Cas9.

Read the full GEN article here.

Australian biotech HaemaLogiX spoke to Scrip about its approach to the multiple myeloma space, and how it differentiates itself with new drug targets.

“There are a lot of drugs for multiple myeloma. It’s, in some ways, a very crowded space,” said CEO Chris Baldwin. “But we’re the only ones who are targeting KMA/LMA. Part of that is due to the extensive patent portfolio that we’ve established and developed over the course of the last 20 years. It means that when we come into the market, we have a very strong differentiator compared to anything out there,” Baldwin continued.

Read the full story here. 

Fredrik Frejd, Chief Scientific Officer at Affibody, talked to Drug Discovery World about how the company’s radiotherapeutic candidate could address some of the limitations inherent in current approaches. 

The field of targeted radiopharmaceuticals has witnessed remarkable growth in recent years, driven by blockbuster successes of Novartis’ Lutathera (lutetium Lu 177 dotatate) and Pluvicto (lutetium Lu 177 vipivotide tetraxetan), which together generated over $2 billion in sales in 2024.  

This commercial validation has sparked intense interest from both pharmaceutical companies and investors, with multiple billion-dollar acquisitions in the radiopharmaceutical space signalling confidence in the therapeutic approach. 

Read the full story here. 

CuraCell was recently featured in a wide ranging article in Labiotech on TIL therapy. 

While many TIL developers are looking to treat melanoma first, the Swedish biotech is the first to take on prostate cancer. Its prime candidate CC-38 is being developed to address immunologically ‘cold’ solid tumors.

“While CAR-T therapies are clinically established in hematologic cancers, their efficacy in solid tumors – particularly immunologically cold tumors – remains unproven due to challenges such as limited tumor infiltration, antigen heterogeneity, and complex multi-step manufacturing processes. TIL therapies overcome these barriers by using naturally tumour-adapted T cells that can effectively infiltrate the tumour microenvironment and, through their polyclonal nature, recognize multiple tumour antigens, thereby reducing immune escape and improving outcomes in heterogeneous cancers,” said Jonas Båtelson, CEO and co-founder of CuraCell. 

For more information on the TIL development landscape, read the whole article here.